Cost-effectiveness of strategies for testing current hepatitis C virus infection

Hepatology

Volumn 62, Issue 5, 2015, Pages 1396-1404

  Chapko, Michael K ^a   Dufour, D Robert ^b   Hatia, Rikita I ^c   Drobeniuc, Jan ^c   Ward, John W ^c   Teo, Chong Gee ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HEALTH CARE COST; HEPATITIS C; HEPATITIS C RAPID TEST; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY ANALYZER; INTERMETHOD COMPARISON; LABORATORY TEST; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEIC ACID TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; VEIN PUNCTURE; BLOOD; COST BENEFIT ANALYSIS; HOSPITAL INFORMATION SYSTEM;

HEPATITIS C ANTIBODY; VIRUS RNA;

COST-BENEFIT ANALYSIS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; POINT-OF-CARE SYSTEMS; RNA, VIRAL;

EID: 84945209056     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27966     Document Type: Article

References (28)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
2. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, et al.; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014;58:1055-1061.
3. Ward JW. Testing for HCV: the first step in preventing disease transmission and improving health outcomes for HCV-infected individuals. Antivir Ther 2012;17:1397-1401.
4. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al.; Centers for Disease Control and Prevention (CDC). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61(No. RR-4):1-32. Erratum in: MMWR Recomm Rep. 2012;61:886.
5. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012;156:263-270.
6. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013;62:362-365.
7. Chapko MK, Sloan KL, Davison JW, Dufour DR, Bankson DD, Rigsby M, Dominitz JA; Hepatitis C Resource Center Program, Department of Veterans Affairs. Cost effectiveness of testing strategies for chronic hepatitis C. Am J Gastroenterol 2005;100:607-615.
8. Teo CG. Changing strategies for hepatitis C testing. Antivir Ther 2012;17:1391-1395.
9. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012;157:558-566.
10. O'Connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG, et al. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening in emergency settings. Transfusion 2013;53:505-517.
11. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed April 24, 2014.
12. World Health Organization. A systematic review of immediate HCV RNA testing following HCV antibody compared with HCV RNA testing at time of assessment for HCV therapy. Geneva, Switzerland: World Health Organization; 2014.
13. Rondahl E, Gruber M, Joelsson S, Sundqvist M, Åkerlind B, Cardell K, et al. The risk of HCV RNA contamination in serology screening instruments with a fixed needle for sample transfer. J Clin Virol 2014;60:172-173.
14. Cartwright EJ, Rentsch C, Rimland D. Hepatitis C virus screening practices and seropositivity among US veterans born during 1945-1965. BMC Res Notes 2014;7:449.
15. Gale HB, Dufour DR, Qazi NN, Kan VL. Comparison of serial hepatitis C virus detection in samples submitted through serology for reflex confirmation versus samples directly submitted for quantitation. J Clin Microbiol 2011;49:3036-3039.
16. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-96.
17. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
18. Seeff L, Hollinger F, Alter H, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-463.
19. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, Margolis HS. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006;131:478-484.
20. Galbraith JW, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015;61:776-782.
21. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed September 19, 2014.
22. Honeycutt, AA, Harris JL, Khavjou O, Buffington J, Jones TS, Rein DB. The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep 2007;122S(Suppl 2):55-62.
23. Tiger Medical. BD 366415 Vacutainer Glass Citrate Tube, 13 x 75mm, 4.5mL, One box of 100. Available at: http://www.tigermedical.com/Products/Vacutainer-Glass-Citrate-Tube__BD366393-.aspx?ProductVariantId=e4fe6ee9-199b-4552-8981-e2f0d00b0493&gclid=CLSfuJSi9cACFVJo7Aod0joA-g. Accessed September 22, 2014.
24. Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health 2014;39:922-934.
25. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-1564.
26. Drobnik A, Judd C, Banach D, Egger J, Konty D, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health 2011;101:2151-2155.
27. Rongey C, Kanwal F, Hoang T, Gifford A, Asch S. Viral RNA testing in hepatitis C antibody-positive veterans. Am J Prev Med 2009;36:235-238.
28. Gao F, Talbot EA, Loring CH, Power JJ, Dionne-Odom J, Alroy-Preis S, et al. Performance of the OraQuick HCV rapid antibody test for screening exposed patients in a hepatitis C outbreak investigation. J Clin Microbiol 2014;52:2650-2652.